ESMO 2023 | The future of artificial intelligence in prostate cancer

Charles Parker, MBBS, UCL Cancer Institute, London, UK, highlights the potential real-world applications of multimodal artificial intelligence (MMAI)-derived models for prostate cancer. Following on from the STAMPEDE trials (NCT00268476), which assessed the utility of AI in analyzing biopsy samples, further studies will evaluate their effectiveness in clinical practice. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.